Brexit: A Serious Threat to Patients
As the UK extracts itself from the European Union, key figures from the country’s life sciences sector are split on the implications of Brexit for their industry. “The UK pharmaceutical…
Address: Medawar Centre, Robert Robinson Avenue, The Oxford Science Park, Oxford, OX4 4GA,United Kingdom
Tel: +44 (0) 1865 783 000
Web: http://www.oxfordbiomedica.co.uk/
Oxford BioMedica has established a platform of technologies in gene delivery and immunotherapy, protected by an extensive intellectual property estate. Through in-house and collaborative development, the Company has a broad pipeline of gene-based product candidates for the treatment of age-related or inherited neurodegenerative and ocular diseases. In addition, Oxford BioMedica and its collaborators are developing novel targeted therapies and therapeutic vaccines to treat multiple types of cancer.
Oxford BioMedica’s two lead programmes are a gene therapy for Parkinson’s disease (ProSavin®) in Phase I/II development and a therapeutic cancer vaccine (TroVax®) in Phase II development.
The other products include RetinoStat®, StarGen™, UshStat™, EncorStat™, MoNuDin®, Hi-8® MEL, MetXia®, EndoAngio-GT and Targeted Antibody Therapy.
As the UK extracts itself from the European Union, key figures from the country’s life sciences sector are split on the implications of Brexit for their industry. “The UK pharmaceutical…
Chris Molloy, chief executive of the Medicines Discovery Catapult (MDC), discusses its role within the UK as a center for applied medical R&D and the future of the country’s drug…
Confirming Eisai’s commitment to keeping its EMEA headquarters in the UK, Gary Hendler, chairman and CEO EMEA, and Nick Burgin, COO and president of global value and access stress how…
Only 14 months in position, UK country president at Novartis, Haseeb Ahmad, shares insights into the company’s new strategy. He further analyses how Brexit can be a catalysing force for…
Recently appointed CEO of Health Innovation Manchester, Ben Bridgewater explains the organization’s goal of improving the lives of the people of Greater Manchester by ensuring a constant pipeline of innovation,…
Taking the conversation beyond Brexit, His Excellency Lars Thuesen, ambassador of Denmark to the UK, highlights the solid ties that have linked both countries since the Danes invaded the island…
The Ambassador of Switzerland to the UK, Alexandre Fasel, discloses what has been achieved so far with the ‘Mind the Gap’ strategy, aimed at safeguarding British-Swiss economic and business…
Steve Bates, CEO of the UK BioIndustry Association (BIA) for over five years, shares the importance of the UK’s status as a global life science hub, the long-term government actions…
After a series of recent acquisitions, developing a diverse portfolio comprising four business areas; including OTC and branded prescription medicines, Mylan UK’s country manager, Jean-Yves Brault, takes a step back…
Hugo Fry, managing director of Sanofi UK, details the impact of the company’s changing structure, the continued relevance of the UK market despite the challenges around Brexit, and the significance…
With an appetite to take the next step in its rapid development, EUSA Pharma has already established itself as a leading rare-disease and oncology biotech company in just a short…
Mike Thompson, chief executive of the Association of the British Pharmaceutical Industry (ABPI) reveals his staunch faith in the British health service but calls for the NHS to welcome and…
See our Cookie Privacy Policy Here
